Meda acquisition bolsters portfolio, expands capabilities in OTC, women’s health, respiratory, allergy, dermatology and pain-management
The close of Mylan’s deal to acquire Meda marks the beginning of another exciting chapter as we work to create better health for a better world. We are once again proving that we are stronger together as we now offer a portfolio of more than 2,700 branded, generic and over-the-counter products.
Access to healthcare is a right, not a privilege, so we are excited about Meda’s complementary strengths and what it means for the patients we serve around the world. This deal allows us to strengthen our business in the markets we already serve around the world and to establish our presence in several emerging markets, including China, Mexico, Russia and Turkey, as well as parts of the Middle East and Southeast Asia. Combined, we will reach more than 165 countries and territories and are positioned better than ever to set new standards in healthcare and provide 7 billion people access to high quality medicine.
Our broad and impressive portfolio of medicines, integrated global R&D and manufacturing platform, insistence on quality in all things and long tradition of fighting for industry-shaping policy improvements makes us a standout company amongst our peers. Like our recent acquisitions of other complementary businesses, such as those from Abbott, Agila, Famy Care and Renaissance, Meda builds on these strengths. Our global workforce - now more than 40,000 strong – continues to help drive Mylan to be an innovative, patient-focused healthcare company.
As we continue to set new standards in healthcare, our presence in women’s health, respiratory, allergy, dermatology and pain-management will be significantly enhanced. Mylan’s powerful platform will increasingly bring more value to our customers through a broader range of products and services and total patient and pharmacy solutions, the result of which will make the Mylan brand an important part of the patient journey.